ArticleInternational journal of cancer2026
The Predictive Value of the Tumor-Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early identification of neoadjuvant therapy non-response via multimodal immune-imaging biomarkers in breast cancer.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Approximately 75% of breast cancers are hormone receptor-positive (HR+). Endocrine therapy may be administered to improve survival. Neoadjuvant therapy may enable breast- and axilla-conserving surgery, but identifying who will benefit remains challenging. This study evaluates the predictive value of the tumor-stroma ratio (TSR) for response to neoadjuvant endocrine therapy (NET) and examines the accuracy of MRI in predicting (near) pathological complete response (pCR). Women diagnosed between 2014 and 2024 with invasive HR+, human epidermal growth factor 2-negative breast cancer who received NET in two Dutch hospitals were included. A total of 208 women (215 tumors) were included, of whom 81 (37.7%) had a stroma-low tumor and 134 (62.3%) stroma-high. Almost 1 out of 4 stroma-low cases achieved (near) pCR after NET. In both univariable (OR 2.85, 95% CI 1.32-6.15, p = 0.008) and multivariable analysis (OR 3.70, 95% CI 1.54-8.90, p = 0.003), stroma-low tumors showed an increased likelihood of achieving (near) pCR compared to stroma-high tumors. In node-positive patients (n = 117), univariable analysis presented higher odds of pCR in the axilla after NET in the stroma-low group (OR 4.41, 95% CI 1.08-18.08, p = 0.039), although this was not significant in multivariable analysis (p = 0.060). The MRI correctly reported (near) pCR in 12 (75%) stroma-low cases and 8 (35%) stroma-high. Stroma-low patients significantly more often achieved (near) pCR of the tumor and axilla after NET compared to stroma-high patients. The accuracy of MRI to predict (near) pCR was higher in the stroma-low group compared to the stroma-high group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.